Highlights Halucenex is a Psychedelic-Assisted Psychotherapy (PAP) company Halucenex focuses on the commercialisation and R&D of novel psychedelic molecules for the treatment of Post Traumatic...
pharmaceuticals
Open Orphan lands another £2.5m flu challenge study contract
Open Orphan (LSE:ORPH) Open Orphan has won a flu human challenge study contract worth £2.5 million with an unnamed US biotech. The study will be carried out by subsidiary hVIVO at the group’s...
Open Orphan extends pharmacometrics relationship with tier 1 German pharma company
Open Orphan (LSE:ORPH) Open Orphan bounced back by 6.6% on Friday morning after announcing an extension of its relationship with a tier 1 German pharmaceutical company. The pharmaceutical services...
Open Orphan reveals transformational Covid-19 vaccine contract with UK government
Tuesday saw Open Orphan (LSE:ORPH) reveal a transformational Covid-19 vaccination contract with the UK government that could be worth up to £40 million. The first part of the contract will see Open...
Open Orphan hits record highs after winning £4.3m vaccine contract
Open Orphan (LSE:ORPH) shot up to record highs on Monday morning after unveiling a £4.3 million contract with a global top ten vaccine company. Shares in the pharmaceutical services player have been...
Round-up: Busy week for Open Orphan as it pushes forward Covid and oncology arms (ORPH)
Open Orphan (LSE:ORPH) has confirmed that it is in advanced negotiations with the UK government for a coronavirus challenge study. In a Thursday update in response to a spike in its share price, the...
Special Report: 6 Reasons Why XPhyto Therapeutics Can Enhance Your Portfolio – (CSE:XPHY | OTC:XPHYF | FSE:4XT)
Huge biotech potential at XPhyto Therapeutics (CSE:XPHY | OTC:XPHYF | FSE:4XT) Biotechs are among the most profitable, highest-margin businesses on earth. Why? Exclusivity and first-mover advantage....
Key human challenge expert Adrian Wildfire rejoins hVIVO for Open Orphan boost (ORPH)
Anglo-Irish contract research pharma group Open Orphan (LSE:ORPH) has received another boost as key human challenge study expert Adrian Wildfire rejoins the team. Mr Wildfire left Open Orphan...
Open Orphan’s hVIVO expands lab growth revenue with three new contract wins (ORPH)
Open Orphan (LSE:ORPH) has signed new laboratory contracts for its London virology clinic, extending up a new area of business for the pharma services firm. A Tuesday morning RNS detailed how...